和誉-B宣布,欧洲药品管理局已授予其自主研发的Lavengratinib(研发代号ABSK061)孤儿药资格认定,该药物拟用于软骨发育不全的治疗。
和誉-B宣布,欧洲药品管理局已授予其自主研发的Lavengratinib(研发代号ABSK061)孤儿药资格认定,该药物拟用于软骨发育不全的治疗。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.